These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17155983)

  • 21. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
    Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer.
    Yap WN; Zaiden N; Luk SY; Lee DT; Ling MT; Wong YC; Yap YL
    Pharmacology; 2010; 85(4):248-58. PubMed ID: 20375535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
    Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boc-lysinated-betulonic acid: a potent, anti-prostate cancer agent.
    Saxena BB; Zhu L; Hao M; Kisilis E; Katdare M; Oktem O; Bomshteyn A; Rathnam P
    Bioorg Med Chem; 2006 Sep; 14(18):6349-58. PubMed ID: 16777417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumour effect of electrochemotherapy with bleomycin on human prostate cancer xenograft.
    Ueki T; Uemura H; Nagashima Y; Ohta S; Ishiguro H; Kubota Y
    BJU Int; 2008 Nov; 102(10):1467-71. PubMed ID: 18549430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
    Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
    Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis.
    McCulloch DR; Opeskin K; Thompson EW; Williams ED
    Prostate; 2005 Sep; 65(1):35-43. PubMed ID: 15800936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
    Wainstein MA; He F; Robinson D; Kung HJ; Schwartz S; Giaconia JM; Edgehouse NL; Pretlow TP; Bodner DR; Kursh ED
    Cancer Res; 1994 Dec; 54(23):6049-52. PubMed ID: 7525052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion.
    Papo N; Braunstein A; Eshhar Z; Shai Y
    Cancer Res; 2004 Aug; 64(16):5779-86. PubMed ID: 15313920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory mechanisms of Agaricus blazei Murill on the growth of prostate cancer in vitro and in vivo.
    Yu CH; Kan SF; Shu CH; Lu TJ; Sun-Hwang L; Wang PS
    J Nutr Biochem; 2009 Oct; 20(10):753-64. PubMed ID: 18926679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
    Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S
    Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.